---
title: "Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285286415.md"
description: "William Blair analyst Andy Hsieh has reiterated a Buy rating on Exelixis (EXEL) due to strong commercial performance and clinical momentum, particularly from the STELLAR-304 trial. He notes the encouraging event rate in the trial and the durability of the Cabometyx franchise, despite some temporary challenges. Hsieh also emphasizes the value from Exelixis's share repurchase program, which includes a new $750 million authorization through 2027. Goldman Sachs also maintains a Buy rating with a $50 price target."
datetime: "2026-05-06T00:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285286415.md)
  - [en](https://longbridge.com/en/news/285286415.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285286415.md)
---

# Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases

William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating on April 21.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Andy Hsieh has given his Buy rating due to a combination of factors tied to Exelixis’s commercial strength and clinical momentum. He believes the slower-than-anticipated event rate in the Phase III STELLAR-304 trial of zanzalintinib plus Opdivo in non-clear cell renal cell carcinoma is an encouraging signal, especially given supportive prior data from PAPMET and Merck’s KEYNOTE-B61 that validate this therapeutic approach.

He also highlights the durability of the Cabometyx franchise, which continues to generate substantial revenue despite temporary headwinds from inventory dynamics and higher gross-to-net adjustments. After normalizing for these seasonal effects, he views underlying demand as solid, and he sees incremental shareholder value from Exelixis’s substantial ongoing share repurchase program, including a new $750 million authorization through 2027.

In another report released on April 21, Goldman Sachs also maintained a Buy rating on the stock with a $50.00 price target.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)

## Related News & Research

- [Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL](https://longbridge.com/en/news/286523415.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)